ASCO 2025 Conference Review – Breast Cancer Focus
In this review:
– Treatment rechallenge after trastuzumab deruxtecan-related ILD
– Vepdegestrant vs fulvestrant in ER-positive/HER2-negative advanced breast cancer
– INAVO120: Final overall survival analysis
– Fulvestrant + ipatasertib for advanced ER-positive/HER2-negative breast cancer
– Sacituzumab govitecan + pembrolizumab in PD-L1-positive advanced TNBC
– Trastuzumab deruxtecan + pertuzumab for first-line treatment of HER2-positive advanced breast cancer
– Adjuvant exemestane + OFS in premenopausal ER-positive early breast cancer
– Elinzanetant for VMS associated with adjuvant endocrine therapy
– ctDNA-guided detection of emerging resistance: SERENA-6 trial
Expert contributor
Dr Sheridan Wilson
Dr Sheridan Wilson is a Medical Oncologist specialising in the treatment of breast cancer. Sheridan graduated from the Auckland University School of Medicine in 2003 and became a Fellow of the Royal Australasian College of Physicians in 2012. Between 2013 and 2014, Sheridan completed a clinical research fellowship in breast cancer at The British Columbia […]
Latest Publications and Videos
Stay up to date with our latest clinical information.
Explore Research Review Publications and Videos
Dive into our publications and videos content from over 50 areas of medicine including Cardiology, Diabetes, Oncology, Haematology and Psychiatry.
Terms and Conditions
Website terms of use
By using our website, you agree to follow these terms and conditions.
Privacy policy
We take your privacy seriously. To understand how we collect, use, and protect your information, please read our Privacy Policy, which is part of these terms.
Copyright and use of website content
The content of our website is protected by copyright, trademarks, and other legal rights. You can: view, download, or print a single copy of content for your personal or professional use.
You cannot: copy, modify, or distribute website content, or use our website content for commercial purposes or in other works without permission.
Links to third-party websites
The Research Review website may link to third-party websites for your convenience. However:
We do not endorse or approve their products, services, or actions.
We are not responsible for their content or how they operate.
There is no formal partnership between us and third parties unless we clearly state otherwise.
Disclaimer and limitation of liability
We do our best to keep the information on our website accurate, but we do not guarantee that it is always correct or up to date.
To the fullest extent allowed by law, we are not responsible for:
Any loss, damage, or costs you may suffer from using (or being unable to use) our website.
Any decisions you make based on the information provided.
Any business losses, such as lost profits, lost data, or business interruptions.
Governing law
These terms are governed by New Zealand law. If there is a dispute, it must be resolved in a New Zealand court.
